Tenofovir-based alternate therapies for chronic hepatitis B patients with partial virological response to entecavir

Journal of Viral Hepatitis

Volumn 22, Issue 8, 2015, Pages 675-681

  Lu, L ^a,b   Yip, B ^c   Trinh, H ^d   Pan, C Q ^e   Han, S H B ^f   Wong, C C ^g   Li, J ^h   Chan, S ⁱ   Krishnan, G ^j   Nguyen, M H ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^c EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^d San Jose Gastroenterology   (United States)

^e NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^f UCLA MEDICAL CENTER   (United States)

^g MD ^*  (United States)

^h PALO ALTO MEDICAL FOUNDATION   (United States)

ⁱ Medical Procare   (United States)

^j STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

chronic hepatitis B; entecavir; partial virological response; switch; tenofovir

Indexed keywords

ENTECAVIR; HEPATITIS B(E) ANTIGEN; TENOFOVIR; VIRUS DNA; ANTIVIRUS AGENT; GUANINE;

ADULT; ARTICLE; ASIAN; CHRONIC HEPATITIS B; COHORT ANALYSIS; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE; UNITED STATES; VIRUS INHIBITION; VIRUS LOAD; AGED; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG THERAPY; HEPATITIS B, CHRONIC; MIDDLE AGED; PROCEDURES; RETROSPECTIVE STUDY; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG THERAPY; FEMALE; GUANINE; HEPATITIS B, CHRONIC; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TENOFOVIR; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 84934762470     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12368     Document Type: Article

References (22)

1. Hepatitis B [Internet]. [Place unknown]: World Health Organization; [Date unknown] [updated 2013 July]. Available at: http://www.who.int/mediacentre/factsheets/fs204/en/ (accessed 6 June 2014).
2. Beasley RP,. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer 1988; 61: 1942-1956.
3. Lok ASF, McMahon BJ,. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-662.
4. Iloeje UH, Yang HI, Su J, et al,. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 678-686.
5. Liaw YF,. Hepatitis B virus replication and liver disease progression: the impact of antiviral therapy. Antivir Ther 2006; 11: 669-679.
6. Mommeja-Marin H, Mondou E, Blum MR, Rousseau F,. Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature. Hepatology 2003; 37: 1309-1319.
7. Woo G, Tomlinson G, Nishikawa Y, et al,. Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and bayesian meta-analyses. Gastroenterology 2010; 139: 1218-1229.
8. Keeffe EB, Dieterich DT, Han SH, et al,. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol 2008; 6: 1315-1341.
9. Luo J, Li X, Wu Y, et al,. Efficacy of entecavir treatment for up to 5 years in nucleos(t)ide-Naïve chronic hepatitis B patients in real life. Int J Med Sci 2013; 10: 427-433.
10. Gish R, Lok AS, Chang TT, et al,. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007; 133: 1437-1444.
11. Colonno RJ, Rose R, Baldick CJ, et al,. Entecavir resistance is rare in nucleoside naïve patients with hepatitis B. Hepatology 2006; 44: 1656-1665.
12. Bartholomeusz A, Locarnini SA,. Antiviral drug resistance: clinical consequences and molecular aspects. Semin Liver Dis 2006; 26: 162-170.
13. Chen CH, Hu TH, Hung CH, Wang JH, Lu SN, Lee CM,. Antiviral effect of entecavir in nucleos(t)ide analogue-naïve and nucleos(t)ide analogue-experienced chronic hepatitis B patients without virological response at week 24 or 48 of therapy. J Viral Hepat 2014; 21: e55-e64.
14. Ha NB, Ha NB, Trinh HN, Nguyen HA, Nguyen KK, Nguyen MH,. Response to higher dose of entecavir 1.0 mg daily in patients with partial response to entecavir 0.5 mg daily. J Clin Gastroenterol 2013; 47: 461-465.
15. Pan CQ, Hu KQ, Yu AS, Chen W, Bunchorntavakul C, Reddy KR,. Response to tenofovir monotherapy in chronic hepatitis B patients with prior suboptimal response to entecavir. J Viral Hepat 2012; 19: 213-219.
16. Petersen J, Ratziu V, Buti M, et al,. Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: an international multicenter cohort study. J Hepatol 2012; 56: 520-526.
17. Yip B, Chaung K, Wong CR, et al,. Tenofovir monotherapy and tenofovir plus entecavir combination as rescue therapy for entecavir partial responders. Dig Dis Sci 2012; 57: 3011-3016.
18. EASL clinical practice guidelines. Management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-185.
19. Zoutendijk R, Reijnders JG, Brown A, et al,. Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naïve patients with a partial virological response. Hepatology 2011; 54: 443-451.
20. Yang YJ, Shim JH, Kim KM, Lim YS, Lee HC,. Assessment of current criteria for primary nonresponse in chronic hepatitis B patients receiving entecavir therapy. Hepatology 2014; 59: 1303-1310.
21. Ha NB, Ha NB, Garcia RT, et al,. Medication nonadherence with long-term management of patients with hepatitis B e antigen-negative chronic hepatitis B. Dig Dis Sci 2011; 56: 2423-2431.
22. Hongthanakorn C, Chotiyaputta W, Oberhelman K, et al,. Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice. Hepatology 2011; 53: 1854-1863.